Acta Diabetologica

, Volume 46, Issue 1, pp 1–11 | Cite as

The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?

  • Manfredi Rizzo
  • Ali A. Rizvi
  • Giovam Battista Rini
  • Kaspar Berneis
Review Article


The metabolic syndrome consists of a constellation of clinical and biochemical risk factors that cluster together and heighten the risk for atherogenesis, cardiovascular diseases, and diabetes. Established risk cardiovascular factors like hypertension, atherogenic dyslipidaemia, and glucose intolerance occur in the setting of insulin resistance and central adiposity, with genetic and environmental influences modulating the ultimate risk. Chronic insults to the endothelium take its toll in the form of silent as well as clinically evident cardiovascular events. The cellular and vascular accompaniments have shed some light into the underlying pathophysiology. Heightened, low-grade inflammatory processes as well as a continuum of vascular insults ranging from early endothelial derangements to advanced atherosclerosis have been examined. In recent years there has been an explosion of basic and clinical knowledge related to the metabolic syndrome. Although dyslipidaemia is considered a traditional risk component for the syndrome, its qualitative aspects, genetically determined subfractions, and variation in proatherogenic tendency have generated renewed interest and debate. New targets within the dyslipidaemic spectrum that have differing clinical relevance are being evaluated. The effect of heredity, lifestyle changes, pharmacotherapeutic agents, and supplements is being investigated. Further research into the impact of dyslipidemia and inflammation as both pathophysiologic risk factors and objects for targeted therapy in the metabolic syndrome should deepen our understanding and unravel answers to the underlying dynamics in this global epidemic.


Metabolic syndrome Insulin resistance Dyslipidemia Atherosclerosis Adipocytokines 


  1. 1.
    Cameron AJ, Shaw JE, Zimmet PZ (2004) The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33:351–375PubMedGoogle Scholar
  2. 2.
    International Diabetes Federation (2006) The IDF consensus worldwide definition of the metabolic syndrome. IDF Executive Office, Brussels, Belgium. Available at Accessed 7 Feb 2008
  3. 3.
    Reaven GM (2004) Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor’s clothes fit? Diabetes Care 27:1011–1012PubMedGoogle Scholar
  4. 4.
    Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whiner PH (2004) Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease. Diabetologia 47(9):1557–1565PubMedGoogle Scholar
  5. 5.
    Sjoholm A, Nystrom T (2005) Endothelial inflammation in insulin resistance. Lancet 365(9459):610–612PubMedGoogle Scholar
  6. 6.
    Ceriello A, Motz E (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24:816–823PubMedGoogle Scholar
  7. 7.
    Shinozaki K, Kashiwagi A, Masada M, Okamura T (2004) Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 4:1–11PubMedGoogle Scholar
  8. 8.
    Black PH (2003) The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 17(5):350–364PubMedGoogle Scholar
  9. 9.
    Fernandez-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24(3):278–301PubMedGoogle Scholar
  10. 10.
    Chan JC, Cheung JC, Stehouwer CD, Emeis JJ, Tong PC, Ko GT, Yudkin JS (2002) The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome: an analysis by structural equation modeling. Int J Obes Relat Metab Disord 26(7):994–1008PubMedGoogle Scholar
  11. 11.
    Tracy RP (2003) Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 134:10–17PubMedGoogle Scholar
  12. 12.
    Mallika V, Goswami B, Rajappa M (2007) Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 58(5):513–522PubMedGoogle Scholar
  13. 13.
    Nishida M, Moriyama T, Ishii K, Takashima S, Yoshizaki K, Sugita Y, Yamauchi-Takihara K (2007) Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta 384(1–2):99–104PubMedGoogle Scholar
  14. 14.
    Muntner P, He J, Chen J, Fonseca V, Whelton PK (2004) Prevalence of non-traditional cardiovascular risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14(9):686–695PubMedGoogle Scholar
  15. 15.
    Hsueh WA, Quinones MJ (2003) Role of endothelial dysfunction in insulin resistance. Am J Cardiol 92:10J–17JPubMedGoogle Scholar
  16. 16.
    Gustafson B, Hammarstedt A, Andersson CX, Smith U (2007) Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27(11):2276–2283PubMedGoogle Scholar
  17. 17.
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565PubMedGoogle Scholar
  18. 18.
    Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other markers of inflammation in the prediction of coronary artery disease. N Engl J Med 350:1387–1397PubMedGoogle Scholar
  19. 19.
    Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689PubMedGoogle Scholar
  20. 20.
    Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C (2007) Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 52(6):1590–1600PubMedGoogle Scholar
  21. 21.
    Ninomiya T, Kiyohara Y (2007) Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr 2(2):104–107PubMedGoogle Scholar
  22. 22.
    Dai DF, Lin JW, Kao JH, Hsu CN, Chiang FT, Lin JL, Chou YH, Hsu KL, Tseng CD, Tseng YZ, Hwang JJ (2007) The effects of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular events. J Clin Endocrinol Metab 92(7):2532–2537PubMedGoogle Scholar
  23. 23.
    Mosca L (2002) C-reactive protein—to screen or not to screen? N Engl J Med 347:1615–1617PubMedGoogle Scholar
  24. 24.
    Tall AR (2004) C-reactive protein reassessed. N Engl J Med 350:1450–1452PubMedGoogle Scholar
  25. 25.
    Ridker PM, Wilson PW, Grundy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825PubMedGoogle Scholar
  26. 26.
    Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedGoogle Scholar
  27. 27.
    Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMedGoogle Scholar
  28. 28.
    Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14, 719 initially healthy American women. Circulation 107:391–397PubMedGoogle Scholar
  29. 29.
    Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385PubMedGoogle Scholar
  30. 30.
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565PubMedGoogle Scholar
  31. 31.
    McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P (2002) Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908–2912PubMedGoogle Scholar
  32. 32.
    Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM (2003) C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23:650–655PubMedGoogle Scholar
  33. 33.
    Hackam DG, Anand SS (2003) Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 290(7):932–940PubMedGoogle Scholar
  34. 34.
    Bhatt DL, Topol EJ (2002) Need to test the inflammation hypothesis. Circulation 106:136–140PubMedGoogle Scholar
  35. 35.
    Krauss RM, Burke DJ (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23:97–104PubMedGoogle Scholar
  36. 36.
    Rizzo M, Berneis K (2006) Low-density-lipoproteins size and cardiovascular risk assessment. QJM-Int J Med 99:1–14Google Scholar
  37. 37.
    Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J (1990) Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83:59–67PubMedGoogle Scholar
  38. 38.
    Rizzo M, Berneis K (2007) Who needs to care about small, dense low density lipoproteins? Int J Clin Pract 61:1949–1956PubMedGoogle Scholar
  39. 39.
    National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421Google Scholar
  40. 40.
    Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495–506PubMedGoogle Scholar
  41. 41.
    Rizzo M, Berneis K (2005) Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscl Thromb 12:237–239Google Scholar
  42. 42.
    Sattar N, Petrie JR, Jaap AJ (1998) The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 138:229–235PubMedGoogle Scholar
  43. 43.
    Superko HR (1996) Beyond LDL cholesterol reduction. Circulation 94:2351–2354PubMedGoogle Scholar
  44. 44.
    Barter P (2006) Options for therapeutic intervention: how effective are the different agents? Eur Heart J Suppl 8:F47–F53Google Scholar
  45. 45.
    Bjornheden T, Babyi A, Bondjers G, Wiklund O (1996) Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123:43–56PubMedGoogle Scholar
  46. 46.
    Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ (1998) Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39:1263–1273PubMedGoogle Scholar
  47. 47.
    Camejo G, Lopez A, Lopez F, Quinones J (1985) Interaction of low density lipoproteins with arterial proteoglycans. The role of charge and sialic acid content. Atherosclerosis 55:93–105Google Scholar
  48. 48.
    Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM (2001) Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110:103–110PubMedGoogle Scholar
  49. 49.
    Tribble DL, Holl LG, Wood PD, Krauss RM (1992) Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93:189–199PubMedGoogle Scholar
  50. 50.
    de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF (1991) Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298–306PubMedGoogle Scholar
  51. 51.
    Sacks FM, Campos H (2003) Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocr Metab 88:4525–4532PubMedGoogle Scholar
  52. 52.
    Wierzbicki T (2008) Detection of small, dense LDL-cholesterol: is it necessary to determine particle size? Future Lipidol 3:23–25Google Scholar
  53. 53.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedGoogle Scholar
  54. 54.
    Haffner SM, Mykkanen L, Robbins D, Valdez R, Miettinen H, Howard BV, Stern MP, Bowsher R (1995) A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 38:1328–1336PubMedGoogle Scholar
  55. 55.
    Hulthe J, Bokemark L, Wikstrand J, Fagerberg B (2000) The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20:2140–2147PubMedGoogle Scholar
  56. 56.
    World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. World Health Org, GenevaGoogle Scholar
  57. 57.
    Garin MC, Kalix B, Morabia A, James RW (2005) Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 90:2264–2269PubMedGoogle Scholar
  58. 58.
    Slapikas R, Luksiene D, Slapikiene B, Babarskiene MR, Grybauskiene R, Linoniene L (2005) Prevalence of cardiovascular risk factors in coronary heart disease patients with different low-density lipoprotein phenotypes. Medicina (Kaunas) 41:925–931Google Scholar
  59. 59.
    Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M (2006) Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 55:885–891PubMedGoogle Scholar
  60. 60.
    Julius U, Dittrich M, Pietzsch J (2007) Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int J Clin Pract 61:1798–1804PubMedGoogle Scholar
  61. 61.
    Gentile M, Panico S, Jossa F, Mattiello A, Ubaldi S, Marotta G, Pauciullo P, Rubba P (2008) Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. Clin Chim Acta 388:179–183PubMedGoogle Scholar
  62. 62.
    Nesto RW (2005) Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5:379–387PubMedGoogle Scholar
  63. 63.
    Davidson MH, Toth PP (2004) Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 47: 73–104Google Scholar
  64. 64.
    Rizzo M, Berneis K (2007) The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 23:1103–1111PubMedGoogle Scholar
  65. 65.
    Towne SP, Thara E (2008) Do statins reduce events in patients with metabolic syndrome? Curr Atheroscler Rep 10(1):39–44PubMedGoogle Scholar
  66. 66.
    Rizzo M, Berneis K (2006) The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drug Ther 20:205–217Google Scholar
  67. 67.
    Rosenson RS, Otvos JD, Freedman DS (2002) Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90(2):89–94PubMedGoogle Scholar
  68. 68.
    Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM (1996) Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 94:2146–2153PubMedGoogle Scholar
  69. 69.
    Zambon A, Hokanson JE, Brown BG, Brunzell JD (1999) Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959–1964PubMedGoogle Scholar
  70. 70.
    Marais AD (2000) Therapeutic modulation of low-density lipoprotein size. Curr Opin Lipidol 11:597–602PubMedGoogle Scholar
  71. 71.
    Manninen V, Tenkanen L, Koskinen P et al (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 85:37–45PubMedGoogle Scholar
  72. 72.
    Tenkanen L, Manttari M, Manninen V (1995) Some coronary risk factors related to the insulin resistance syndrome and the treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 92:1779–1785PubMedGoogle Scholar
  73. 73.
    Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans affairs high-density lipoprotein cholesterol intervention trials study group. N Engl J Med 341:410–418PubMedGoogle Scholar
  74. 74.
    Tavridou A, Manolopoulos VG (2008) Novel molecules targeting dyslipidemia and atherosclerosis. Curr Med Chem 15(8):792–802PubMedGoogle Scholar
  75. 75.
    Drexler AJ, Nesto RW, Abrahamson MJ et al (2005) Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord 3(2):147–173PubMedGoogle Scholar
  76. 76.
    Krauss RM (2004) Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496–1504PubMedGoogle Scholar
  77. 77.
    Aronoff S, Rosenblatt S, Braithwaite S et al (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605–1611PubMedGoogle Scholar
  78. 78.
    Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA et al (2002) Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 18:127–134PubMedGoogle Scholar
  79. 79.
    Goldberg RB, Kendall DM, Deeg MA et al (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554PubMedGoogle Scholar
  80. 80.
    Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097–2104PubMedGoogle Scholar
  81. 81.
    Deeg MA, Buse JB, Goldberg RB et al (2007) On behalf of the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30:2458–2464PubMedGoogle Scholar
  82. 82.
    Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, Christ ER (2008) Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type-2 diabetes. Expert Opin Pharmacother 9:343–349PubMedGoogle Scholar
  83. 83.
    Pritchett AM, Foreyt JP, Mann DL (2005) Treatment of the metabolic syndrome: the impact of lifestyle modification. Curr Atheroscler Rep 7(2):95–102PubMedGoogle Scholar
  84. 84.
    Chu JW, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Tsao PS (2005) Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res 2(1):37–41PubMedGoogle Scholar
  85. 85.
    Arner P (2003) The adipocyte in insulin reistance: key molecules and the impact of the thiazolidinediones. TRENDS in Endocrinol Metab 14(3):137–145Google Scholar
  86. 86.
    Iushibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A (2002) Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40:687–693Google Scholar
  87. 87.
    Staels B (2007) PPAR agonists and the metabolic syndrome. Therapie 62(4):319–326PubMedCrossRefGoogle Scholar
  88. 88.
    Plutzky J (2007) Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR-alpha. Diab Vasc Dis Res 4(Suppl 3):S12–S14PubMedGoogle Scholar
  89. 89.
    Maki KC (2004) Fibrates for treatment of the metabolic syndrome. Curr Atheroscler Rep J 6(1):45–51Google Scholar
  90. 90.
    Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344:1383–1389Google Scholar
  91. 91.
    Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, Nishino M, Ito H, Tanouchi J, Nanto S, Hori M, Osaka Acute Coronary Insufficiency Study (OACIS) Group (2005) Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 96(5):617–621PubMedGoogle Scholar
  92. 92.
    Elrod JW, Lefer DJ (2005) The effects of statins on endothelium, inflammation, and cardioprotection. Drugs News Perspect 18(4):229–236Google Scholar
  93. 93.
    Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S (2001) Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933–1935PubMedGoogle Scholar
  94. 94.
    Bougoulia M, Triantos A, Koliakos G (2006) Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 5(4):259–269Google Scholar
  95. 95.
    Valsamakis G, McTernan PG, Chetty R et al (2004) Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53(4):430–434PubMedGoogle Scholar
  96. 96.
    Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31(Suppl 2):S229–S240PubMedGoogle Scholar
  97. 97.
    Perkins JM, Davis SN (2008) Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep 8(1):12–19PubMedGoogle Scholar
  98. 98.
    Dagenais NJ, Jamali F (2005) Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 25(9):1213–1229PubMedGoogle Scholar
  99. 99.
    Sierra C, de la Sierra A (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens 14(5):435–441PubMedGoogle Scholar
  100. 100.
    American College of Endocrinology (ACE) (2003) Position statement on the insulin resistance syndrome. Endocr Pract 9(No. 3):236–252Google Scholar
  101. 101.
    van Oostrom AJ, van Wijk J, Cabezas MC (2004) Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 64(Suppl 2):19–41PubMedGoogle Scholar
  102. 102.
    Garg R, Tripathy D, Dandona P (2003) Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 4(6):487–492PubMedGoogle Scholar
  103. 103.
    Hughes S (2000) Novel risk factors for coronary heart disease: emerging connections. J Cardiovasc Nurs 14(2):91–103PubMedGoogle Scholar
  104. 104.
    Muzzio ML, Berg G, Zago V et al (2007) Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women. Clin Chim Acta 381(2):157–163PubMedGoogle Scholar
  105. 105.
    Guldiken B, Guldiken S, Turgut B et al (2008) The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 59(2):224–229PubMedGoogle Scholar
  106. 106.
    Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA (2006) Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring) 14(12):2127–2131Google Scholar
  107. 107.
    Dandona P (2008) Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc 83(3):333–342PubMedCrossRefGoogle Scholar
  108. 108.
    Paumelle R, Staels B (2008) Cross-talk between statins and PPAR-alpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 18(3):73–78PubMedGoogle Scholar
  109. 109.
    Okopien B, Krysiak R, Kowalski J et al (2004) The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327–335PubMedGoogle Scholar
  110. 110.
    Paumelle R, Blanquart C, Briand O et al (2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98:361–369PubMedGoogle Scholar
  111. 111.
    Yano M, Matsumura T, Senokuchi T et al (2007) Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase ½ and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 100:1442–1451PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Manfredi Rizzo
    • 1
  • Ali A. Rizvi
    • 2
  • Giovam Battista Rini
    • 1
  • Kaspar Berneis
    • 3
  1. 1.Department of Clinical Medicine and Emerging DiseasesUniversity of PalermoPalermoItaly
  2. 2.Division of Endocrinology, Diabetes, and MetabolismUniversity of South Carolina School of MedicineColumbiaUSA
  3. 3.Clinics for Endocrinology, Diabetes and Clinical NutritionZurich University HospitalZurichSwitzerland

Personalised recommendations